Clinical Trials Browser

NIH × Breast Neoplasms, Male × Bevacizumab × Clear all

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00368875 2015-11-05

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1/2 Completed

54 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Phase NA Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT00017394 2013-01-17

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT01093235 2010-03-25

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Postoperative Complications, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Cardiotoxicity